Patient Satisfaction and Patients' Family or Significant Other Perceptions After OnabotulinumtoxinA Treatment: A Prospective Cross-Sectional Study

BACKGROUND OnabotulinumtoxinA treatment is associated with improved emotional well-being in patients. OBJECTIVE This study aimed to determine satisfaction with onabotulinumtoxinA treatment in patients naive to neurotoxin treatment and patients with previous experience with the procedure and evaluate treatment impact on patients' partners, "significant others," or close family members. MATERIALS AND METHODS Patients' satisfaction and their family's/significant other's perception to treatment outcome were assessed in a prospective, cross-sectional study using standardized questionnaires. RESULTS OnabotulinumtoxinA treatment was associated with high patient satisfaction ranging from 80% to 100%. Study patients (61 patients) reported that their faces appeared to be more balanced and symmetrical (mean difference, 1.05) and that they looked much better in photographs (mean difference, 1.43), with their significant others also noting the improvement in appearance. Overall, 98% of patients expressed that they would undergo retreatment, and 100% expressed that they would recommend the procedure to others. The main obstacle for treatment repetition was economic constraints (26%). CONCLUSION OnabotulinumtoxinA treatment is one of the most precise and predictable cosmetic treatments available, with high patient satisfaction (97%). A positive outcome of onabotulinumtoxinA treatment, as expressed by patients surveyed using standardized questionnaires, was the appreciation and acceptance by those in close contact with them. Address correspondence and reprint requests to: José R. Montes, MD, FACS, FACCS, Ophthalmology Dpeartment, University of Puerto Rico, 735 Ponce de León Avenue, Suite 813, San Juan, Puerto Rico 00917, or e-mail: jrmontes@jrmontes.com J.R. Montes is a speaker and trainer for Allergan, Galderma, and Merz. The study was conducted without any support from Allergan, manufacturer of onabotulinumtoxinA (Botox). Nevertheless, Allergan funded the publication of the study. R.V. Ubale is an employee of Cactus Communications who was funded by Allergan for providing writing and editorial assistance. The authors have indicated no significant interest with commercial supporters. © 2019 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

http://bit.ly/2TKFcNH